IGF-I (30-41) TFA(82177-09-1,FREE)
CAS No. ——
IGF-I (30-41) TFA(82177-09-1,FREE)( Insulin-like Growth Factor I (30-41) (TFA) )
Catalog No. M29820 CAS No. ——
IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameIGF-I (30-41) TFA(82177-09-1,FREE)
-
NoteResearch use only, not for human use.
-
Brief DescriptionIGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).
-
DescriptionIGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).
-
In Vitro——
-
In Vivo——
-
SynonymsInsulin-like Growth Factor I (30-41) (TFA)
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight1380.36
-
Molecular FormulaC51H83N19O19.C2HF3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:{Gly}{Tyr}{Gly}{Ser}{Ser}{Ser}{Arg}{Arg}{Ala}{Pro}{Gln}{Thr}
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Puche JE, et al. Human conditions of insulin-like growth factor-I (IGF-I) deficiency. J Transl Med. 2012 Nov 14;10:224.
molnova catalog
related products
-
4-Demethyldehydropod...
4'-Demethyldehydropodophyllotoxin is an aryltetralin lignan that can be isolated from leaves of Podophyllum hexandrum. 4'-Demethyldehydropodophyllotoxin exhibits some cytotoxic and antitumour activity.
-
Sinefungin
Sinefungin is an effective inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral multiplication.
-
Ganoderenic acid B
Ganoderenic acid B, a natural product derived from Ganoderma lucidum, can work by inhibiting the transport function of ABCB1 and enhancing the cytotoxicity of chemotherapy drugs against AbCB1-mediated multidrug resistant cancer cells.
Cart
sales@molnova.com